Leukemia inhibitory factor (LIF)

Cytokine and Growth Factor Reviews

Volumn 26, Issue 5, 2015, Pages 533-544

  Nicola, Nicos A ^a,b   Babon, Jeffrey J ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Embryonic stem cells; JAK STAT SOCS; Leukemia inhibitory factor; LIF receptor; Nerve and muscle; Pregnancy

Indexed keywords

CARDIOTROPHIN 1; CARDIOTROPHIN LIKE CYTOKINE; CILIARY NEUROTROPHIC FACTOR RECEPTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR; FOCAL ADHESION KINASE 1; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; KRUPPEL LIKE FACTOR 4; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; NERVE GROWTH FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; SCLEROSTIN; STAT PROTEIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; IL6ST PROTEIN, HUMAN; LIF PROTEIN, HUMAN; LIF PROTEIN, MOUSE;

BINDING AFFINITY; BONE REMODELING; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; EMBRYONIC STEM CELL; ENZYME ACTIVATION; HEMATOPOIETIC SYSTEM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NEUROMUSCULAR SYSTEM; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLASTOCYST; GENE EXPRESSION REGULATION; GENETICS; HUMAN EMBRYONIC STEM CELL; IMMUNOLOGY; KNOCKOUT MOUSE; MOUSE; MOUSE EMBRYONIC STEM CELL; NIDATION;

ANIMALS; BLASTOCYST; CYTOKINE RECEPTOR GP130; EMBRYO IMPLANTATION; GENE EXPRESSION REGULATION; HUMAN EMBRYONIC STEM CELLS; HUMANS; JANUS KINASES; LEUKEMIA INHIBITORY FACTOR; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MOUSE EMBRYONIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, OSM-LIF; STAT TRANSCRIPTION FACTORS;

EID: 84941917883     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.07.001     Document Type: Review

References (135)

1. Gearing D.P., Gough N.M., King J.A., Hilton D.J., Nicola N.A., Simpson R.J., et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 1987, 6:3995-4002.
2. Smith A.G., Heath J.K., Donaldson D.D., Wong G.G., Moreau J., Stahl M., et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 1988, 336:688-690.
3. Moreau J.F., Bonneville M., Godard A., Gascan H., Gruart V., Moore M.A., et al. Characterization of a factor produced by human T cell clones exhibiting eosinophil-activating and burst-promoting activities. J. Immunol. 1987, 138:3844-3849.
4. Baumann H., Onorato V., Gauldie J., Jahreis G.P. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J. Biol. Chem. 1987, 262:9756-9768.
5. Patterson P.H., Chun L.L. The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons. I. Effects of conditioned medium. Dev. Biol. 1977, 56:263-280.
6. Patterson P.H., Chun L.L. The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons. II. Developmental aspects. Dev. Biol. 1977, 60:473-481.
7. Mori M., Yamaguchi K., Abe K. Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem. Biophys. Res. Commun. 1989, 160:1085-1092.
8. Robinson R.C., Grey L.M., Staunton D., Vankelecom H., Vernallis A.B., Moreau J.F., et al. The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding. Cell 1994, 77:1101-1116.
9. Hinds M.G., Maurer T., Zhang J.G., Nicola N.A., Norton R.S. Solution structure of leukemia inhibitory factor. J. Biol. Chem. 1998, 273:13738-13745.
10. Boulanger M.J., Bankovich A.J., Kortemme T., Baker D., Garcia K.C. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol. Cell. 2003, 12:577-589.
11. Gearing D.P., Comeau M.R., Friend D.J., Gimpel S.D., Thut C.J., McGourty J., et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992, 255:1434-1437.
12. Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003, 300:2101-2104.
13. Chow D., Ho J., Nguyen Pham T.L., Rose-John S., Garcia K.C. In vitro reconstitution of recognition and activation complexes between interleukin-6 and gp130. Biochemistry 2001, 40:7593-7603.
14. Matadeen R., Hon W.C., Heath J.K., Jones E.Y., Fuller S. The dynamics of signal triggering in a gp130-receptor complex. Structure 2007, 15:441-448.
15. Skiniotis G., Lupardus P.J., Martick M., Walz T., Garcia K.C. Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Mol. Cell. 2008, 31:737-748.
16. Gearing D.P., Thut C.J., VandeBos T., Gimpel S.D., Delaney P.B., King J., et al. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J. 1991, 10:2839-2848.
17. Xu Y., Kershaw N.J., Luo C.S., Soo P., Pocock M.J., Czabotar P.E., et al. Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. J. Biol. Chem. 2010, 285:21214-21218.
18. Stahl N., Boulton T.G., Farruggella T., Ip N.Y., Davis S., Witthuhn B.A., et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994, 263:92-95.
19. Huyton T., Zhang J.G., Luo C.S., Lou M.Z., Hilton D.J., Nicola N.A., et al. An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12737-12742.
20. Boulanger M.J., Garcia K.C. Shared cytokine signaling receptors: structural insights from the gp130 system. Adv. Protein Chem. 2004, 68:107-146.
21. Hilton D.J., Nicola N.A., Metcalf D. Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J. Cell. Physiol. 1991, 146:207-215.
22. Hilton D.J., Nicola N.A. Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution. J. Biol. Chem. 1992, 267:10238-10247.
23. Lupardus P.J., Skiniotis G., Rice A.J., Thomas C., Fischer S., Walz T., et al. Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Ralpha cytokine receptor complex, and the receptor-Jak1 holocomplex. Structure 2011, 19:45-55.
24. Gouin F., Couillaud S., Cottrel M., Godard A., Passuti N., Heymann D. Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. Cytokine 1999, 11:282-289.
25. Ni H., Ding N.Z., Harper M.J., Yang Z.M. Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy. Mol. Reprod. Dev. 2002, 63:143-150.
26. Scott R.L., Gurusinghe A.D., Rudvosky A.A., Kozlakivsky V., Murray S.S., Satoh M., et al. Expression of leukemia inhibitory factor receptor mRNA in sensory dorsal root ganglion and spinal motor neurons of the neonatal rat. Neurosci. Lett. 2000, 295:49-53.
27. Williams R.L., Hilton D.J., Pease S., Willson T.A., Stewart C.L., Gearing D.P., et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 1988, 336:684-687.
28. Wilks A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:1603-1607.
29. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
30. Chung B.M., Kang H.C., Han S.Y., Heo H.S., Lee J.J., Jeon J., et al. Jak2 and Tyk2 are necessary for lineage-specific differentiation, but not for the maintenance of self-renewal of mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 2006, 351:682-688.
31. Takahashi Y., Takahashi M., Carpino N., Jou S.T., Chao J.R., Tanaka S., et al. Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway. Mol. Endocrinol. 2008, 22:1673-1681.
32. Ernst M., Oates A., Dunn A.R. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J. Biol. Chem. 1996, 271:30136-30143.
33. Williams N.K., Bamert R.S., Patel O., Wang C., Walden P.M., Wilks A.F., et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 2009, 387:219-232.
34. Thoma B., Bird T.A., Friend D.J., Gearing D.P., Dower S.K. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J. Biol. Chem. 1994, 269:6215-6222.
35. Oh H., Fujio Y., Kunisada K., Hirota H., Matsui H., Kishimoto T., et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J. Biol. Chem. 1998, 273:9703-9710.
36. Fahmi A., Smart N., Punn A., Jabr R., Marber M., Heads R. p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cell. Signalling 2013, 25:898-909.
37. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
38. Hirai H., Karian P., Kikyo N. Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor. Biochem. J. 2011, 438:11-23.
39. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
40. Raz R., Lee C.K., Cannizzaro L.A., d'Eustachio P., Levy D.E. Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:2846-2851.
41. Niwa H., Burdon T., Chambers I., Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998, 12:2048-2060.
42. Schmitz J., Dahmen H., Grimm C., Gendo C., Muller-Newen G., Heinrich P.C., et al. The cytoplasmic tyrosine motifs is full-length glycoprotein 130 have different roles in IL-6 signal transduction. J. Immunol. 2000, 164:848-854.
43. Haan S., Hemmann U., Hassiepen U., Schaper F., Schneider-Mergener J., Wollmer A., et al. Characterization and binding specificity of the monomeric STAT3-SH2 domain. J. Biol. Chem. 1999, 274:1342-1348.
44. Stahl N., Farruggella T.J., Boulton T.G., Zhong Z., Darnell J.E., Yancopoulos G.D. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995, 267:1349-1353.
45. Haan S., Kortylewski M., Behrmann I., Muller-Esterl W., Heinrich P.C., Schaper F. Cytoplasmic STAT proteins associate prior to activation. Biochem. J. 2000, 345:417-421.
46. Starr R., Willson T.A., Viney E.M., Murray L.J.L., Rayner J.R., Jenkins B.J., et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921.
47. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387:921-924.
48. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929.
49. Hilton D.J., Richardson R.T., Alexander W.S., Viney E.M., Willson T.A., Sprigg N.S., et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:114-119.
50. Babon J.J., Kershaw N.J., Murphy J.M., Varghese L.N., Laktyushin A., Young S.N., et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 2012, 36:239-250.
51. Kershaw N.J., Murphy J.M., Liau N.P., Varghese L.N., Laktyushin A., Whitlock E.L., et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 2013, 20:469-476.
52. Kershaw N.J., Laktyushin A., Nicola N.A., Babon J.J. Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates. Growth Factors 2014, 32:1-10.
53. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 2000, 275:12848-12856.
54. Roberts A.W., Robb L., Rakar S., Hartley L., Cluse L., Nicola N.A., et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9324-9329.
55. Takahashi Y., Carpino N., Cross J.C., Torres M., Parganas E., Ihle J.N. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J. 2003, 22:372-384.
56. Matsuda T., Nakamura T., Nakao K., Arai T., Katsuki M., Heike T., et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999, 18:4261-4269.
57. Paling N.R.D., Wheadon H., Bone H.K., Welham M.J. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J. Biol. Chem. 2004, 279:48063-48070.
58. Watanabe S., Umehara H., Murayama K., Okabe M., Kimura T., Nakano T. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 2006, 25:2697-2707.
59. Schaper F., Gendo C., Eck M., Schmitz J., Grimm C., Anhuf D., et al. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem. J. 1998, 335:557-565.
60. Schiemann W.P., Bartoe J.L., Nathanson N.M. Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase. Evidence for participation of multiple signaling pathways which converge at Ras. J. Biol. Chem. 1997, 272:16631-16636.
61. Anhuf D., Weissenbach M., Schmitz J., Sobota R., Hermanns H.M., Radtke S., et al. Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: Structural receptor requirements for signal attenuation. J. Immunol. 2000, 165:2535-2543.
62. Bartoe J.L., Nathanson N.M. Differential regulation of leukemia inhibitory factor-stimulated neuronal gene expression by protein phosphatases SHP-1 and SHP-2 through mitogen-activated protein kinase-dependent and -independent pathways. J. Neurochem. 2000, 74:2021-2032.
63. Neel B.G., Gu H.H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci 2003, 28:284-293.
64. Lehmann U., Schmitz J., Weissenbach M., Sobota R.M., Hortner M., Friederichs K., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J. Biol. Chem. 2003, 278:661-671.
65. Burdon T., Stracey C., Chambers I., Nichols J., Smith A. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Dev. Biol. 1999, 210:30-43.
66. Meloche S., Vella F.D., Voisin L., Ang S.L., Saba-El-Leil M. Erk2 signaling and early embryo stem cell self-renewal. Cell Cycle 2004, 3:241-243.
67. Forrai A., Boyle K., Hart A.H., Hartley L., Rakar S., Willson T.A., et al. Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. Stem Cells 2006, 24:604-614.
68. Ying Q.L., Wray J., Nichols J., Batlle-Morera L., Doble B., Woodgett J., et al. The ground state of embryonic stem cell self-renewal. Nature 2008, 453:519-523.
69. Nichols J., Chambers I., Taga T., Smith A. Physiological rationale for responsiveness of mouse embryonic stem cells to gp130 cytokines. Development 2001, 128:2333-2339.
70. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
71. Yang J., van Oosten A.L., Theunissen T.W., Guo G., Silva J.C., Smith A. Stat3 activation is limiting for reprogramming to ground state pluripotency. Cell Stem Cell 2010, 7:319-328.
72. Graf U., Casanova E.A., Cinelli P. The role of the leukemia inhibitory factor (LIF)-pathway in derivation and maintenance of murine pluripotent stem cells. Genes 2011, 2:280-297.
73. Matsui Y., Toksoz D., Nishikawa S., Nishikawa S., Williams D., Zsebo K., et al. Effect of Steel factor and leukaemia inhibitory factor on murine primordial germ cells in culture. Nature 1991, 353:750-752.
74. Leitch H.G., Nichols J., Humphreys P., Mulas C., Martello G., Lee C., et al. Rebuilding pluripotency from primordial germ cells. Stem Cell Rep. 2013, 1:66-78.
75. Stewart C.L., Kaspar P., Brunet L.J., Bhatt H., Gadi I., Kontgen F., et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 1992, 359:76-79.
76. Charnock-Jones D.S., Sharkey A.M., Fenwick P., Smith S.K. Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. J. Reprod. Fertil. 1994, 101:421-426.
77. Chen J.R., Cheng J.G., Shatzer T., Sewell L., Hernandez L., Stewart C.L. Leukemia inhibitory factor can substitute for nidatory estrogen and is essential to inducing a receptive uterus for implantation but is not essential for subsequent embryogenesis. Endocrinology 2000, 141:4365-4372.
78. Krishnan T., Winship A., Sonderegger S., Menkhorst E., Horne A.W., Brown J., et al. The role of leukemia inhibitory factor in tubal ectopic pregnancy. Placenta 2013, 34:1014-1019.
79. Laird S.M., Tuckerman E.M., Dalton C.F., Dunphy B.C., Li T.C., Zhang X. The production of leukaemia inhibitory factor by human endometrium: presence in uterine flushings and production by cells in culture. Hum. Reprod. 1997, 12:569-574.
80. Giess R., Tanasescu I., Steck T., Sendtner M. Leukaemia inhibitory factor gene mutations in infertile women. Mol. Hum. Reprod. 1999, 5:581-586.
81. White C.A., Zhang J.G., Salamonsen L.A., Baca M., Fairlie W.D., Metcalf D., et al. Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: a nonhormonal contraceptive strategy. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19357-19362.
82. Lemons A.R., Naz R.K. Birth control vaccine targeting leukemia inhibitory factor. Mol. Reprod. Dev. 2012, 79:97-106.
83. Fitzgerald J.S., Tsareva S.A., Poehlmann T.G., Berod L., Meissner A., Corvinus F.M., et al. Leukemia inhibitory factor triggers activation of signal transducer and activator of transcription 3, proliferation, invasiveness, and altered protease expression in choriocarcinoma cells. Int. J. Biochem. Cell Biol. 2005, 37:2284-2296.
84. Horita H., Kuroda E., Hachisuga T., Kashimura M., Yamashita U. Induction of prostaglandin E2 production by leukemia inhibitory factor promotes migration of first trimester extravillous trophoblast cell line, HTR-8/SVneo. Hum. Reprod. 2007, 22:1801-1809.
85. Robb L., Boyle K., Rakar S., Hartley L., Lochland J., Roberts A.W., et al. Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:16333-16338.
86. Kritikou E.A., Sharkey A., Abell K., Came P.J., Anderson E., Clarkson R.W., et al. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003, 130:3459-3468.
87. Walker E.C., McGregor N.E., Poulton I.J., Solano M., Pompolo S., Fernandes T.J., et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Investig. 2010, 120:582-592.
88. Metcalf D., Gearing D.P. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:5948-5952.
89. Metcalf D., Nicola N.A., Gearing D.P. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 1990, 76:50-56.
90. Sims N.A., Johnson R.W. Leukemia inhibitory factor: a paracrine mediator of bone metabolism. Growth Factors 2012, 30:76-87.
91. Palmqvist P., Persson E., Conaway H.H., Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 2002, 169:3353-3362.
92. Dagoneau N., Scheffer D., Huber C., Al-Gazali L.I., Di Rocco M., Godard A., et al. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am. J. Hum. Genet. 2004, 74:298-305.
93. Chesnokova V., Auernhammer C.J., Melmed S. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 1998, 139:2209-2216.
94. Akita S., Readhead C., Stefaneanu L., Fine J., Tampanaru-Sarmesiu A., Kovacs K., et al. Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function. A model for human pituitary Rathke's cysts. J. Clin. Investig. 1997, 99:2462-2469.
95. Yano H., Readhead C., Nakashima M., Ren S.G., Melmed S. Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. Mol. Endocrinol. 1998, 12:1708-1720.
96. Patterson P.H., Nawa H. Neuronal differentiation factors/cytokines and synaptic plasticity. Cell 1993, 72Suppl:123-137.
97. Rao M.S., Sun Y., Escary J.L., Perreau J., Tresser S., Patterson P.H., et al. Leukemia inhibitory factor mediates an injury response but not a target-directed developmental transmitter switch in sympathetic neurons. Neuron 1993, 11:1175-1185.
98. Murphy M., Reid K., Hilton D.J., Bartlett P.F. Generation of sensory neurons is stimulated by leukemia inhibitory factor. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:3498-3501.
99. Murphy M., Dutton R., Koblar S., Cheema S., Bartlett P. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog. Neurobiol. 1997, 52:355-378.
100. Hendry I.A., Murphy M., Hilton D.J., Nicola N.A., Bartlett P.F. Binding and retrograde transport of leukemia inhibitory factor by the sensory nervous system. J. Neurosci. 1992, 12:3427-3434. (the official journal of the Society for Neuroscience).
101. Curtis R., Scherer S.S., Somogyi R., Adryan K.M., Ip N.Y., Zhu Y., et al. Retrograde axonal transport of LIF is increased by peripheral nerve injury: correlation with increased LIF expression in distal nerve. Neuron 1994, 12:191-204.
102. Richards L.J., Kilpatrick T.J., Dutton R., Tan S.S., Gearing D.P., Bartlett P.F., et al. Leukaemia inhibitory factor or related factors promote the differentiation of neuronal and astrocytic precursors within the developing murine spinal cord. Eur. J. Neurosci. 1996, 8:291-299.
103. Cheema S.S., Richards L.J., Murphy M., Bartlett P.F. Leukaemia inhibitory factor rescues motoneurones from axotomy-induced cell death. NeuroReport 1994, 5:989-992.
104. Kwon Y.W., Abbondanzo S.J., Stewart C.L., Gurney M.E. Leukemia inhibitory factor influences the timing of programmed synapses withdrawal from neonatal muscles. J. Neurobiol. 1995, 28:35-50.
105. Sendtner M., Gotz R., Holtmann B., Escary J.L., Masu Y., Carroll P., et al. Cryptic physiological trophic support of motoneurons by LIF revealed by double gene targeting of CNTF and LIF. Curr. Biol.: CB 1996, 6:686-694.
106. Li M., Sendtner M., Smith A. Essential function of LIF receptor in motor neurons. Nature 1995, 378:724-727.
107. DeChiara T.M., Vejsada R., Poueymirou W.T., Acheson A., Suri C., Conover J.C., et al. Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell 1995, 83:313-322.
108. Bauer S., Patterson P.H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J. Neurosci. 2006, 26:12089-12099.
109. Yoshida T., Satoh M., Nakagaito Y., Kuno H., Takeuchi M. Cytokines affecting survival and differentiation of an astrocyte progenitor cell line. Brain Res. Dev. Brain Res. 1993, 76:147-150.
110. Ware C.B., Horowitz M.C., Renshaw B.R., Hunt J.S., Liggitt D., Koblar S.A., et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 1995, 121:1283-1299.
111. Mayer M., Bhakoo K., Noble M. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 1994, 120:143-153.
112. Deverman B.E., Patterson P.H. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J. Neurosci. 2012, 32:2100-2109. (the official journal of the Society for Neuroscience).
113. Bugga L., Gadient R.A., Kwan K., Stewart C.L., Patterson P.H. Analysis of neuronal and glial phenotypes in brains of mice deficient in leukemia inhibitory factor. J. Neurobiol. 1998, 36:509-524.
114. Ishibashi T., Lee P.R., Baba H., Fields R.D. Leukemia inhibitory factor regulates the timing of oligodendrocyte development and myelination in the postnatal optic nerve. J. Neurosci. Res. 2009, 87:3343-3355.
115. Austin L., Burgess A.W. Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J. Neurol. Sci. 1991, 101:193-197.
116. Barnard W., Bower J., Brown M.A., Murphy M., Austin L. Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses lif mRNA. J. Neurol. Sci. 1994, 123:108-113.
117. Finkelstein D.I., Bartlett P.F., Horne M.K., Cheema S.S. Leukemia inhibitory factor is a myotrophic and neurotrophic agent that enhances the reinnervation of muscle in the rat. J. Neurosci. Res. 1996, 46:122-128.
118. Sakuma K., Watanabe K., Sano M., Uramoto I., Totsuka T. Differential adaptation of growth and differentiation factor 8/myostatin, fibroblast growth factor 6 and leukemia inhibitory factor in overloaded, regenerating and denervated rat muscles. Biochim. Biophys. Acta 2000, 1497:77-88.
119. Spangenburg E.E., Booth F.W. Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(-/-) mouse. Cytokine 2006, 34:125-130.
120. Kurek J.B., Bower J.J., Romanella M., Koentgen F., Murphy M., Austin L. The role of leukemia inhibitory factor in skeletal muscle regeneration. Muscle Nerve 1997, 20:815-822.
121. Sheng Z., Pennica D., Wood W.I., Chien K.R. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996, 122:419-428.
122. Nelson S.K., Wong G.H., McCord J.M. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J. Mol. Cell. Cardiol. 1995, 27:223-229.
123. Zou Y., Takano H., Mizukami M., Akazawa H., Qin Y., Toko H., et al. Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 2003, 108:748-753.
124. Mohri T., Fujio Y., Maeda M., Ito T., Iwakura T., Oshima Y., et al. Leukemia inhibitory factor induces endothelial differentiation in cardiac stem cells. J. Biol. Chem. 2006, 281:6442-6447.
125. Leary A.G., Wong G.G., Clark S.C., Smith A.G., Ogawa M. Leukemia inhibitory factor differentiation-inhibiting activity/human interleukin for DA cells augments proliferation of human hematopoietic stem cells. Blood 1990, 75:1960-1964.
126. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 2003, 21:5-14.
127. Escary J.L., Perreau J., Dumenil D., Ezine S., Brulet P. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 1993, 363:361-364.
128. Metcalfe S.M. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun. 2011, 12:157-168.
129. Weber M.A., Schnyder-Candrian S., Schnyder B., Quesniaux V., Poli V., Stewart C.L., et al. Endogenous leukemia inhibitory factor attenuates endotoxin response. Lab. Investig. 2005, 85:276-284.
130. Liu S.C., Tsang N.M., Chiang W.C., Chang K.P., Hsueh C., Liang Y., et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J. Clin. Investig. 2013, 123:5269-5283.
131. Wu L., Yu H., Zhao Y., Zhang C., Wang J., Yue X., et al. HIF-2alpha mediates hypoxia-induced LIF expression in human colorectal cancer cells. Oncotarget 2015, 6:4406-4417.
132. Yu H., Yue X., Zhao Y., Li X., Wu L., Zhang C., et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat. Commun. 2014, 5:5218.
133. Davis I.D., Kiers L., MacGregor L., Quinn M., Arezzo J., Green M., et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin. Cancer Res. 2005, 11:1890-1898.
134. Gunawardana D.H., Basser R.L., Davis I.D., Cebon J., Mitchell P., Underhill C., et al. A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clin. Cancer Res. 2003, 9:2056-2065.
135. Brinsden P.R., Alam V., de Moustier B., Engrand P. Recombinant human leukemia inhibitory factor does not improve implantation and pregnancy outcomes after assisted reproductive techniques in women with recurrent unexplained implantation failure. Fertil. Steril. 2009, 91:1445-1447.